
C-Max Pharmaceuticals Private Limited
Founded in 2010 and headquartered in Maharashtra, India.
Founded in 2010 and headquartered in Maharashtra, India.
Mumbai, Maharashtra, India
+91-XXXXXXXXXX
U52310MH2010PTC209610
209610
Private Limited Indian Non-Government Company
29 Oct 2010
30 Sep 2013
31 Mar 2013
Unlisted
Roc Mumbai
Name | Designation | Appointment Date | Status |
---|---|---|---|
Parvezahmad Farooqui ![]() | Director | 29-Oct-2010 | Current |
Khan Gufran ![]() | Director | 29-Oct-2010 | Current |
Enhance accessibility to C-Max Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets | |||||||
Profit or Loss | |||||||
Net Worth | |||||||
EBITDA |
Unlock access to C-Max Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Khan Gufran is a mutual person
Khan Gufran is a mutual person
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with C-Max Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of C-Max Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped C-Max Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
C-Max Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2013 as per latest MCA records.
C-Max Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2013 with Roc Mumbai.
Parvezahmad Sekhbaboo Farooqui was appointed as a Director was appointed as a Director on 29 Oct 2010 & has been associated with this company since 14 years 5 months .
Khan Gufran was appointed as a Director was appointed as a Director on 29 Oct 2010 & has been associated with this company since 14 years 5 months .
C-Max Pharmaceuticals Private Limited was registered on 29 Oct 2010 with Roc Mumbai & aged 14 years 5 months as per MCA records.
C-Max Pharmaceuticals Private Limited was incorporated on 29 Oct 2010.
The authorized share capital of C-Max Pharmaceuticals Private Limited is ₹ 0.10 M and paid-up capital is ₹ 0.10 M.
Currently 2 directors are associated with C-Max Pharmaceuticals Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of C-Max Pharmaceuticals Private Limited is 106 B Wing Thevar Apartment, Sion Mumbai Link Road Sarvi, Maharashtra, India, 400017.
The corporate identification number (CIN) of C-Max Pharmaceuticals Private Limited is U52310MH2010PTC209610 and the company number is 209610 as per Ministry of Corporate Affairs (MCA).
The most recent Balance Sheet for C-Max Pharmaceuticals Private Limited was filed with the ROC on 31 Mar 2013.